

## AGREEMENT WITH PATIENT ASSOCIATION Project support

This Agreement is made by and between

JANSSEN-CILAG A/S, a company with its registered address at Bregnerødvej 133 2, DK-3460 Birkerød , Denmark, VAT no.: DK19248615 hereinafter "**J&J AFFILIATE**";

and

LYLE LYMFEBKRÆFT OG LEUKÆMI, Banetoften 26, 4700 Næstved, Denmark, Org. ID no.: 31 30 68 33, hereafter referred to as "**Organization**"

J&J AFFILIATE and Organization are individually referred to as a "**Party**", collectively referred to as the "**Parties**".

WHEREAS:

- J&J AFFILIATE is a research-oriented pharmaceutical company active in the development and marketing of medicinal products.
- Organization is a patient organization that serve 2.600 people living with blood cancers such as lymphoma, leukemia or MDS.
- Organization has asked J&J AFFILIATE to support one of its projects and J&J AFFILIATE has agreed to provide support under the terms of this agreement.

THE PARTIES TO THIS AGREEMENT AGREE AS FOLLOWS:

### **Article 1: Scope**

1. Organization will carry out the Project for which J&J AFFILIATE will provide support and Organization shall ensure that the contribution is used in a professional and ethical manner consistent with this Agreement and applicable rules, legislation and code of practice. More details on the Project (including the objective, roles and responsibilities of both parties, contact persons, outputs, reporting and timelines) are included in **Annex 1**,
2. Organization will use the support provided by J&J AFFILIATE exclusively for the purpose of the Project.

## **Article 2: Support**

1. The total amount of support that J&J AFFILIATE will provide for the Project amounts to **75,000.00 DKK**.
2. Further details on the level and type of support, including payment method and timelines, are included in **Annex 1**.
3. Organization and J&J AFFILIATE acknowledge and agree that the support shall not obligate Organization to purchase, use, recommend, or arrange for the use of any products of J&J AFFILIATE.
4. EU and National legislation and codes of practice prohibiting the advertising of prescription-only medicines to the general public, apply. Organization and J&J AFFILIATE acknowledge and agree that J&J AFFILIATE shall not request, nor shall Organization undertake, the promotion of a particular prescription-only medicine.
5. Organization represents and warrants that it is a tax-exempt entity under the applicable laws and that it is authorized to accept support in the form of financial contribution or other support from private companies such as J&J AFFILIATE, and that, to the extent applicable, it has performed the necessary notifications or received the necessary approvals. Organization will also keep J&J AFFILIATE regularly informed of its direct or indirect relationships with government officials and/or government authorities.
6. If any funds provided by J&J AFFILIATE to Organization under this Agreement remain upon completion of the Project, such surplus shall be refunded by Organization to J&J AFFILIATE within forty-five (45) days of completion of the project.

## **Article 3: Use of name and logo or other proprietary materials**

1. Organization will publicly recognize that J&J AFFILIATE provides support for the Project in the following manner by ensuring reporting to the ENLI codex.

## **Article 4: Transparency**

1. In order to create appropriate transparency on the support to patient organizations by J&J AFFILIATE, and in line with the applicable code(s) of practice, J&J AFFILIATE will make the existence of this agreement and details relating thereto publicly available at Janssen Denmark Website [www.janssen.com/denmark](http://www.janssen.com/denmark) and Organization explicitly

agrees with such disclosure. More precisely, J&J AFFILIATE will make the following details publicly available:

- a) Date that the contract was executed;
- b) Name of the patient organization;
- c) Country of the patient organization;
- d) Web address of the patient organization, if available;
- e) Description of the nature and the purpose of the contribution;
- f) Amount as contracted, if financial.

In addition, J&J AFFILIATE will also make copies of this contract available to interested parties upon their request.

2. J&J AFFILIATE is entitled to increase the level of details made publicly available to patient organizations either as required by applicable rules and legislation, or upon notice to Organization.
3. This article shall survive any termination of the Agreement.

#### **Article 5: Term and termination**

1. This Agreement will take effect on the date when the last of the parties has signed, hereafter the Effective Date, and will remain in effect up until the completion of the Project, as described in **Annex 1**.
2. Both parties have the right to terminate this Agreement upon 2 months written notice notified by registered mail. The respective rights and obligations of both parties in case of early termination of the Project or this Agreement are included in **Annex 1**.

#### **Article 8: General Provisions**

1. General Anti-Corruption Compliance Provision

Neither party shall perform any actions that are prohibited by local and other anti-corruption laws (collectively "**Anti-Corruption Laws**") that may be applicable to one or both parties to the Agreement. Without limiting the foregoing, neither party shall make any payments, or offer or transfer anything of value, to any government official or government employee, to any political party official or candidate for political office or to any other third party related to the transaction in a manner that would violate Anti-Corruption Laws.

2. Personal Data

J&J AFFILIATE needs to collect personal information from the Organization, and J&J AFFILIATE and its affiliates will use such information, in order to manage J&J AFFILIATE's relationship with the Organization pursuant to this letter agreement. A list of affiliates is at <http://www.investor.jnj.com/sec.cfm> (click on the link to Form 10K, Exhibit 21, under "SEC Filings"). J&J AFFILIATE may also disclose the Organization's personal information to third-parties service providers, such as technology and marketing service providers, and parties engaged in the organization of events, including hotels and airlines. If the Organization does not provide the personal information requested, J&J AFFILIATE will not be able to fulfill its obligations to the Organization pursuant to this letter agreement. Based on the J&J AFFILIATE's legitimate interests, J&J AFFILIATE may use the Organization's personal information to compile statistical data based on the information in our databases, as well as on surveys, customer feedback questionnaires, and similar communications.

The Organization may contact J&J AFFILIATE with questions or request to review the personal information J&J AFFILIATE has collected and/or to request its correction, deletion, blocking, data portability or restriction at [jacdk@its.jnj.com](mailto:jacdk@its.jnj.com). The Organization may also lodge a complaint with a data protection authority for the Organization's country or region.

The use and disclosure of personal information may involve a transfer to other jurisdictions, including the U.S., which may provide for different data protection rules than in the Organization's country. Appropriate contractual and other measures are in place to protect personal information when it is transferred. The Organization may obtain a copy of these measures by contacting the J&J AFFILIATE's data protection officer responsible for the Organization's country or region, if applicable, at [emeaprivacy@its.jnj.com](mailto:emeaprivacy@its.jnj.com).

J&J AFFILIATE will retain the Organization's personal information for as long as needed or permitted in the light of the purpose(s) for which it was obtained, based on: (i) the length of time J&J AFFILIATE has an ongoing relationship with the Organization; (ii) whether there is a legal obligation to which J&J AFFILIATE is subject; and (iii) whether retention is advisable in light of the J&J AFFILIATE's legal position.

### 3. Pandemic

If either of the Parties is unable to perform its obligations under this Agreement due to its evolving policies related to the COVID-19 health pandemic, or because of uncertainty related to the impact of COVID-19, either Party may terminate this Agreement upon not less than 3 days' written notice to the other, in which case neither Party shall have any further obligations to the other, including any obligation to pay for goods and/or services not actually performed and/or delivered prior to the written notice of termination.

J&J AFFILIATE may cancel any meeting upon notice without liability, cancellation fees or damages, in the event of the COVID-19 health pandemic and/or any other health

pandemic for which the World Health Organization and/or other local governmental and/or health authorities issue travel alerts or warnings recommending against non-essential travel to Event's location and/or against meetings of groups of people, making it inadvisable, illegal, or impossible to provide the facilities or to have the meeting/Event, or if the meeting/Event could create a significant risk to the health and safety of participants.

In case of early termination or cancellation by J&J Affiliate due to the abovementioned reasons, the Recipient will be reimbursed for any actual and documented costs, which are directly related to the Project and have been already incurred and which cannot be recouped through cancellation policies. If the meeting/Event is a physical meeting and is converted into digital form or otherwise converted into a different form than originally agreed upon, the meeting/Event costs and related payment will be re-evaluated by the Parties. In particular, the organizer or the delegated agency shall provide J&J AFFILIATE with a list and detailed breakdown of the actual costs incurred for the provision of the obligations set out in this Agreement to allow performance in the changed form (which are expected to be lower than the costs that may have been incurred for a face-to-face meeting/Event). In case of such conversion to a different meeting/Event form, J&J AFFILIATE shall be obliged to pay only the newly identified amount or shall be entitled to receive reimbursement of the difference between the originally agreed upon contractual amount and the re-evaluated amount within 30 (thirty) days of J&J AFFILIATE's written request to the organizer. Such provisions shall take precedence over any other contracting provisions and/or other agreements and/or understandings that may have been reached between the Parties.

#### 4. Governing Law

This Agreement shall be governed by and construed under the laws of Denmark, without reference to the conflict of law rules.

#### 5. Dispute Resolution

In case of any dispute arising out of or in connection with this Agreement, the Parties shall first attempt (in good faith) to reach an amicable settlement. Should such amicable settlement fail, the courts of Denmark shall have exclusive jurisdiction.

#### 6. **Electronic Signatures**

The Parties explicitly agree to execute this Agreement by way of an electronic signature, and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic pdf-version (using Adobe Sign) which shall be electronically signed by each Party. Each Party hereby acknowledges receipt of the e-signed agreement, electronically signed for approval by both Parties.

**For J&J AFFILIATE:**

*Mikkel Johansen*  
Electronically signed by: Mikkel  
Johansen  
Reason: I acknowledge that my  
electronic signature is the legally  
binding equivalent for my handwritten  
signature  
Date: May 3, 2024 15:15 GMT+2


Market Access & Policy Director

**For J&J AFFILIATE:**

*Julie Brooker*  
Electronically signed by: Julie  
Brooker  
Reason: I acknowledge that my  
electronic signature is the legally  
binding equivalent for my  
handwritten signature  
Date: May 5, 2024 22:39 GMT+2

Country Director

**For ORGANIZATION:**

  
Electronically signed by: Rita  
Christensen  
Reason: I acknowledge that  
my electronic approval is  
legally binding  
Date: May 3, 2024 15:17  
GMT+2

Forkvinde

## Annex 1: Project details



Næstved d. 14. marts 2024

### **Ansøgning om støtte til afholdelse af temadag d. 4. maj 2024 på Scandic Hotel, Odense om Lymfekræft, Leukæmi og MDS.**

Der søges også til redaktionelt arbejde til et efterfølgende nummer af LyLe Fokus, hjemmeside og Facebook samt produktion heraf\*

#### **Baggrund**

Som patientforening er det LyLe's overordnede formål at indhente og formidle information til gavn for patienter, pårørende og andre interesserede. LyLe er en forening, der er tæt på sine medlemmer – patienter og pårørende – og foreningens temamøder er en vigtig del af denne bestræbelse. Med temamøderne, der i princippet er åbne for alle, understreger vi det nære og vedkommende for alle med tilknytning til blodkræft. Desuden ønsker LyLe at opbygge og vedligeholde tætte bånd til de hæmatologiske afdelinger på de store sygehuse.

Vores hjemmeside og bladudgivelser er også en vigtig del af foreningens informationsdeling og stærkt efterspurgt af vores medlemmer. Bladudgivelserne er desuden en måde at styrke foreningens bånd til de hæmatologiske afdelinger på de store sygehuse, da bladene bliver distribueret til afdelingerne, så de også her er tilgængelige for patienter med lymfekræft, leukæmi og MDS og deres pårørende.

Vi bevarer vores ambitionsniveau, som hidtil.

Vores mål er at afholde temamøder og efterfølgende udgive medlemsblade i år og kontinuerligt opdatere og udvide vores hjemmeside, lyle.dk.

Vi søger støtte fra både medicinalindustrien, diverse fonde og støtteordninger, som fx Tips- og Lottomidlerne. Vi lægger vægt på at få støtte fra en mangfoldighed af sponsorer på hver enkelt af vores projekter.

LyLe – Patientforeningen for Lymfekræft, Leukæmi og MDS

Ranøstøp 26, 4700 Næstved, tlf. 31 68 26 00, CVR 31 20 68 32, lyle@lyle.dk, www.lyle.dk



### Projektbeskrivelse

Ansøgning omfatter afholdelse af temamøde samt redaktionelt arbejde til brug i udgivelse af LyLe Fokus samt til brug på lyle.dk og grupper på Facebook, Twitter i det omfang, det er aktuelt og relevant. Ansøgningen omfatter desuden produktion heraf.

LyLe's regionale temamøder er et udtryk for foreningens ønske om i videst muligt omfang at være der, hvor medlemmerne er gennem afholdelse af møder af ca. 7+ timers varighed i samarbejde med foreningens etablerede lokale netværksgrupper og det regionale hæmatologiske specialecenter.

Det er foreningens overordnede formål altid at nytænke og tilpasse sig aktuelle problemstillinger inden for både sygdomsviden og behandling og på den måde imødekomme medlemmernes behov og ønsker. Ved hvert temamøde vil der være separate sessioner for hvert sygdomsområde, det er patienter og de pårørendes ønsker vi altid lytter til.

Med udgangspunkt i den viden, LyLe besidder om medlemmernes ønsker og behov, vil der i samarbejde med forskellige oplægsholdere være særligt fokus på følgende overordnede temaer:

- At have en hæmatologisk sygdom – sidste nye forskningsresultater
- Eksisterende og fremtidige behandlingsmuligheder, som Car-T
- Fokus på blodkræft, senfølger og arbejdsliv
- Der vil endvidere være fokus på en række specifikke sygdomme som:
  - Lymfekræft
  - Akutte Leukæmier og MDS
  - CML
  - CLL

Program eftersendes hermed og vi mangler dog en læge på CLL.

Målgruppe: Mødet er åbent for alle, men henvender sig særligt til blodkræftpatienter og deres pårørende, men også sundhedsfagligt personale og samarbejdspartnere er velkomne. Vi forventer, at der vil være deltagere ved hvert møde.

Tid og sted: Mødet skal afholdes i Odense, Scandic Hotel. I forbindelse med mødet vil vi desuden afholde foreningens årlige generalforsamling.

Oplægsholdere og debat: Fire læger fra det hæmatologiske felt. Denne gang sætter vi også fokus på senfølger, livskvalitet og rettigheder.

Som forening vil vi være repræsenteret med lokale tovholdere fra netværksgrupperne, formand, bestyrelse, referent, fotograf og redaktør/journalist.



**Budget**

Se næste side.

Vi søger støtte fra flere medicinalfirmaer.

**Kontrakt/samarbejdsaftale**

LyLe efterlever enli.dk regler om samarbejde mellem medicinalindustrien og patientforeninger samt egne interne etiske regelsæt (vedhæftet), hvilket medfører indgåelse af kontrakt/samarbejdsaftale og offentliggørelse heraf på foreningens hjemmeside, ligesom der til hver enkelt udgivelse af Lyle Nyt vil blive oplyst om sponsorer.

Næstved, den 14. marts 2024

A handwritten signature in black ink that reads "Rita O. Christensen".

Rita O. Christensen  
Formand

Nu er mine kolleger vendt tilbage, og der er simpelthen et par aspekter, vi må have helt på plads, så eventen kan blive godkendt i systemet.

Vi har desværre lidt travlt, da detaljerne skal være på plads, før eventen løber af staben lørdag, så jeg håber meget, du har mulighed for at vende hurtigt retur, så vi kan nå at få det godkendt i morgen.

Du ved jo, det er vigtigt med detaljerne, så vi må lige hjælpes ad sammen 😊

1. Den vedhæftede invoice her, du sendte, hvor bankoplysninger var på – den er på 50.000, men vi støtter jo med 75.000 DKK. Vil du rette den til, så den stemmer. **Hermed rettet og vedhæftet**
2. Honorar af oplægsholdere: I budgettet står der, at der er sat 15.000 af til honorar af oplægsholdere. Er der nogen af dem, der får honorar – ellers skal vi bede om et opdateret budget, hvor der ikke er honorar til oplægsholdere? Det kan jo godt være, budgettet stadig passer, men nogle af posterne er højere. Hvis oplægsholderne får honorar, så skal vi bare vide hvem. **Honorar er til Charlotte Hammer fra Senfølgeforeningen i første session, og Maj Thorsen, privatpraktiserende socialrådgiver i sidste session.**
3. Desværre må vi ikke give vin eller andre gaver til oplægsholdere – kun honorar. Så vi skal bede jer præcisere, der ikke er vin. **Ingen andre får gaver eller honorar, lægerne giver gratis oplæg.**

### **Payment method:**

J&J AFFILIATE shall pay the Support within 45 days of being issued an invoice. Payments shall be made by bank transfer and only to a bank account held in the name of the Party on Invoice. Invoices should, as a minimum requirement, contain the following items: (a) full name and address of Party issuing the invoice; (b) where applicable tax number of Party issuing the invoice; (c) full name and address of the J&J AFFILIATE or its appointed agent; (d) place and date of invoice; (e) brief description of services invoiced with date of service rendered; and (f) where value added tax (VAT) is applicable, invoicing Party's VAT number, statement of net amounts invoiced, VAT rate, amount and gross amounts. J&J AFFILIATE will inform the Organization in case the invoice needs to be addressed to its appointed agent instead of to J&J AFFILIATE.



Janssen-Cilag A/S  
Att:Ander Zeidler  
3460 Birkerød  
Danmark  
E-mail:AZeidler@ITS.JNJ.com  
VAT Reg. number: 19248615

### FAKTURA

Date 03.05.2024  
Client no 45 2999 8289  
Invoice no 173

Pcs	Item	DKK	Amount
1	Støtte til LYLE's Temadag d. 4. maj i Odense	75.000,00	75.000,00

DKK	75.000,00
VAT	0,00
FREIGHT	0,00
<b>TOTAL</b>	<b>75.000,00</b>

PO NO:

Terms of payment: 8 days net

Payment due:

Bank transfer to **LYLE Patientforeningen for Lymfekræft, Leukæmi og MDS**

Danske Bank reg. no. 1551 account no. 10283701  
Holmens Kanal 2, 1094 København K

SWIFT: **DABADKK**

IBAN: **DK1830000010283701**

Our reference: **Rita O. Christensen**

Tel: **0045 31 68 26 00**

E-Mail: **lyle@lyle.dk** CRV.nr. 31 30 68 33

LyLe – Patientforeningen for Lymfekræft, Leukæmi og MDS  
Banetoften 26 · 4700 Næstved · tlf. 31 68 26 00 · CVR 31 30 68 33 · lyle@lyle.dk · www.lyle.dk

**Reporting:**

Within 1 month from the activity, the organization will write a small report as proof of event. The report should consist of:

- A letter on the organization's own letterhead-paper, signed by them, where they explain how the grant/support was used and confirm that the grant/support (amount) has been used as agreed upon

And at least one of following:

- Final agenda/Advertisement/ Receipts of costs/ detailed financial accounting for use of the support

Those parts can be combined in the same document, but the content must align with the requirements.











# [2062234] Sponsorship - Other


Final Audit Report

2024-05-05


Created:	2024-05-03
By:	J&J ICD system (icdsup@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAABimt7fYXABo-_hhaCzqd5ts5TPfSE85t

## "[2062234] Sponsorship - Other" History

-  Document created by J&J ICD system (icdsup@its.jnj.com)  
2024-05-03 - 12:22:52 PM GMT- IP address: 199.65.128.86
-  Document emailed to Mikkel Johansen (mjohan12@its.jnj.com) for signature  
2024-05-03 - 12:24:35 PM GMT
-  Document emailed to Julie Brooker (jbrooker@its.jnj.com) for signature  
2024-05-03 - 12:24:36 PM GMT
-  Document emailed to Rita Christensen (rita@lyle.dk) for signature  
2024-05-03 - 12:24:36 PM GMT
-  Email viewed by Rita Christensen (rita@lyle.dk)  
2024-05-03 - 1:14:12 PM GMT- IP address: 217.74.152.110
-  Email viewed by Mikkel Johansen (mjohan12@its.jnj.com)  
2024-05-03 - 1:14:41 PM GMT- IP address: 147.161.147.5
-  Mikkel Johansen (mjohan12@its.jnj.com) has agreed to the terms of use and to do business electronically with JOHNSON AND JOHNSON SERVICES, INC.  
2024-05-03 - 1:15:45 PM GMT- IP address: 147.161.147.5
-  Document e-signed by Mikkel Johansen (mjohan12@its.jnj.com)  
Signing reason: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature  
Signature Date: 2024-05-03 - 1:15:45 PM GMT - Time Source: server- IP address: 147.161.147.5
-  Rita Christensen (rita@lyle.dk) has agreed to the terms of use and to do business electronically with JOHNSON AND JOHNSON SERVICES, INC.  
2024-05-03 - 1:17:51 PM GMT- IP address: 217.116.228.12
-  Document e-signed by Rita Christensen (rita@lyle.dk)  
Signing reason: I acknowledge that my electronic approval is legally binding  
Signature Date: 2024-05-03 - 1:17:51 PM GMT - Time Source: server- IP address: 217.116.228.12

 Email viewed by Julie Brooker (jbrooker@its.jnj.com)

2024-05-05 - 8:39:20 PM GMT- IP address: 165.225.194.161

 Julie Brooker (jbrooker@its.jnj.com) has agreed to the terms of use and to do business electronically with JOHNSON AND JOHNSON SERVICES, INC.

2024-05-05 - 8:39:58 PM GMT- IP address: 165.225.194.161

 Document e-signed by Julie Brooker (jbrooker@its.jnj.com)

Signing reason: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature

Signature Date: 2024-05-05 - 8:39:58 PM GMT - Time Source: server- IP address: 165.225.194.161

 Agreement completed.

2024-05-05 - 8:39:58 PM GMT